Schizophrenia - Epidemiology Forecast - 2034

This ‘Schizophrenia - Epidemiology Forecast - 2034’ report delivers an in-depth understanding of schizophrenia, historical and forecasted epidemiology, as well as the trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.

Schizophrenia Understanding

Schizophrenia is a complex and chronic mental disorder characterized by a range of symptoms including hallucinations, delusions, disorganized thinking, and impaired social functioning people globally. Onset typically occurs in late teens to early 20s for men and late 20s to early 30s for women.

Schizophrenia symptoms vary but typically fall into three categories: psychotic (e.g., hallucinations and delusions), negative (e.g., loss of motivation and social withdrawal), and cognitive (e.g., attention and memory problems). Hallucinations involve perceiving things that are not real, such as hearing voices. Delusions are strong, false beliefs. Negative symptoms include loss of motivation and social withdrawal, while cognitive symptoms affect attention and memory, making daily functioning challenging.

The exact cause of schizophrenia remains unclear, but it is believed to result from a combination of genetic, environmental, and neurobiological factors. Abnormalities in brain structure and neurotransmitter systems, particularly dopamine, glutamate, and serotonin, may contribute to the development of this disorder.

Schizophrenia Diagnosis

Diagnosis of schizophrenia involves ruling out other conditions and may include physical exams, blood tests, and psychiatric evaluations. Tools like the Schizophrenia Symptoms Diagnosis Scale (PANSS, CGI, SANS) may also be utilized to assess symptoms and severity.

Schizophrenia Epidemiology Perspective by the publisher

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of schizophrenia, total diagnosed prevalent cases of schizophrenia, gender-specific diagnosed prevalent cases of schizophrenia, and severity-specific diagnosed prevalent cases of schizophrenia in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

Schizophrenia Detailed Epidemiology Segmentation

• According to these estimates, the total diagnosed prevalent cases of schizophrenia in the 7MM were approximately 3,796,850 in 2022. These cases are expected to increase during the study period (2020-2034).
• In 2022, the US accounted for the highest cases of diagnosed prevalent cases of schizophrenia among the 7MM, with nearly 1,412,470 cases, expected to increase by 2034.
• Among EU4 and the UK, Germany had the highest diagnosed population of schizophrenia, with approximately 452,772 cases, followed by the UK with approximately 386,344 cases. On the other hand, Spain had the lowest number of diagnosed schizophrenia cases in the region in 2022.
• Japan accounted for around 795,563 diagnosed prevalent cases of schizophrenia in 2022. These cases are expected to decrease during the forecast period.
• The gender-specific cases of schizophrenia in the US were nearly 655,002 for females and 757,469 for males in 2022 and are expected to increase within the forecast period (2023-2034).
• Among EU4 and the UK, prevalence of diagnosed cases of schizophrenia varies according to severity, with the highest prevalence observed in severe schizophrenia with around 630,955 cases, followed by moderate type with 583,405 cases, and mild with 374,455 cases in 2022. These cases are expected to change during the forecast period (2023-2034).
• In Japan, the severity-specific diagnosed prevalent cases of schizophrenia in 2022 revealed varying levels of symptom severity, with nearly 450,712 cases classified as mild, 173,599 as moderate, and 171,253 as severe in 2022.

Scope of the Report

• The report covers a descriptive overview of schizophrenia, explaining its symptoms, pathophysiology, and various diagnostic approaches.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
• The report assesses the disease risk and burden of schizophrenia.
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report provides the segmentation of the disease epidemiology for the 7MM, by total prevalent cases of schizophrenia, total diagnosed prevalent cases of schizophrenia, gender-specific diagnosed prevalent cases of schizophrenia and severity-specific diagnosed prevalent cases of schizophrenia.

Report Highlights

• Twelve years forecast of schizophrenia
• The 7MM Coverage
• Total Prevalent Cases of Schizophrenia
• Total Diagnosed Prevalent Cases of Schizophrenia
• Gender-specific Diagnosed Prevalent Cases of Schizophrenia
• Severity-specific Diagnosed Prevalent Cases of Schizophrenia

Key Questions Answered

• What are the disease risks and burdens of schizophrenia?
• What is the historical schizophrenia patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of schizophrenia at the 7MM level?
• What growth opportunities will be across the 7MM concerning the patient population with schizophrenia?
• Which country would have the highest diagnosed prevalent population of schizophrenia among the countries mentioned above during the forecast period (2023-2034)?
• At what CAGR is the population expected to grow across the 7MM forecast period (2023-2034)?

Reasons to Buy

The schizophrenia report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the 7MM schizophrenia epidemiology forecast.
• The schizophrenia epidemiology report and model were written and developed by Masters and PhD level epidemiologists.
• The schizophrenia epidemiology model developed by the publisher is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 12-year forecast period using reputable sources.

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of Disease by Segmentation
• Factors Driving Growth in a Specific Patient Population

Geographies Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034